N-ethyl-succinamic acid | 21451-29-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-ethyl-succinamic acid
• 英文别名: N-Aethyl-succinamidsaeure；Bernsteinsaeure-mono-aethylamid；3-(ethylcarbamoyl)propanoic Acid；4-(ethylamino)-4-oxobutanoic acid
• CAS: 21451-29-6
• 化学式: C₆H₁₁NO₃
• mdl: MFCD01343490
• 分子量: 145.158
• InChiKey: HVMGZVKGWSZOFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-ethyl-succinamic acid 、 苯胺 在 氯化亚砜 作用下， 生成 N-ethyl-N'-phenyl-succinamide
  参考文献：
  名称：

  384. N-取代的马来酰亚胺与硫脲的缩合

  摘要：

  DOI：

  10.1039/jr9490001797
• 作为产物：
  描述：

  N-乙基马来酸 在 乙醇 、 铂 作用下， 生成 N-ethyl-succinamic acid
  参考文献：
  名称：

  Marrian, Journal of the Chemical Society, 1949, p. 1799

  摘要：

  DOI：

文献信息

• [EN] IMMUNOPHILIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS DE LIAISON À L'IMMUNOPHILINE ET LEURS UTILISATIONS
  申请人：UNIV CALIFORNIA

  公开号：WO2020163594A1

  公开（公告）日：2020-08-13

  Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.

  本文描述了免疫蛋白结合化合物以及治疗中枢神经系统疾病的方法，包括在主体的中枢神经系统外联合给予一种抗中枢神经系统疾病药物和本文描述的化合物。
• Novel compounds and compositions for treating diseases asociated with protease activity
  申请人：——

  公开号：US20010053779A1

  公开（公告）日：2001-12-20

  Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.

  描述了用于预防和治疗由肥大细胞介导的炎症性疾病的新化合物、组合物和方法。这些化合物、组合物和方法对预防和治疗与呼吸道相关的炎症性疾病（如哮喘和过敏性鼻炎）以及其他类型的免疫介导性炎症性疾病（如类风湿关节炎、结膜炎和炎症性肠病、各种皮肤病症以及某些病毒性疾病）有效。这些化合物包括对肥大细胞蛋白酶组胺酶的有效和选择性抑制剂。用于治疗这些疾病的组合物包括口服、吸入、局部和静脉制剂，以及包含这些制剂的装置。
• [EN] OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE<br/>[FR] THÉRAPIE OLIGONUCLÉOTIDIQUE POUR MALADIE DE WOLMAN ET MALADIE DE STOCKAGE DES ESTERS DU CHOLESTÉROL
  申请人：DEEP GENOMICS INCORPORATED

  公开号：WO2020237391A1

  公开（公告）日：2020-12-03

  The present disclosure provides antisense oligonucleotides, compositions, and methods that target a LIPA intron flanking exon 8, thereby modulating splicing of LIPA pre-mRNA to increase the level of LIPA mRNA molecules having exon 8, e.g., to provide a therapy for Wolman Disease or Cholesteryl Ester Storage Disease. The present disclosure provides an antisense oligonucleotide including a nucleobase sequence at least 70% complementary to a LIPA pre-mRNA target sequence in a 5'-flanking intron, a 3'-flanking intron, or a combination of exon 8 and the 5'-flanking or 3'-flanking intron.

  本公开提供了针对LIPA内含子环绕外显子8的反义寡核苷酸、组合物和方法，从而调节LIPA前mRNA的剪接，增加具有外显子8的LIPA mRNA分子的水平，例如，为Wolman病或胆固醇酯储存病提供治疗。本公开提供了一种包括至少70％与LIPA前mRNA靶序列在5'-环绕内含子、3'-环绕内含子或外显子8和5'-环绕或3'-环绕内含子的组合中互补的核碱序列的反义寡核苷酸。
• [EN] GP120 -BINDING BENZENE COMPOUNDS AND SACCHARIDE COMPOUNDS<br/>[FR] COMPOSÉS DE BENZÈNES ET DE SACCHARIDES SE LIANT À GP120
  申请人：UNIV LEUVEN KATH

  公开号：WO2011085454A1

  公开（公告）日：2011-07-21

  The present invention provides for novel benzene compounds and saccharide compounds and for the use of said compounds for binding, titration (quantification), removing, purifying or separating the glycoprotein gp120, gp120 comprising viruses or cells infected with gp120 comprising viruses. The invention also provides for a method for the detection, binding, titration (quantification), removal, purification or separation of (or directing therapeutic or other agents to) gp120, gp120 comprising viruses or cells infected with gp120 comprising viruses. The invention further provides for the use of the compounds and for methods using the compounds for directing anti -viral drugs or other agents to gp120 comprising viruses or to gp120 comprising virus - infected cells. The present invention also provides processes for the preparation of said novel compounds.

  本发明提供了新型苯化合物和糖化合物，并用于结合、滴定（定量）、去除、纯化或分离含有糖蛋白gp120的化合物的用途，该gp120包括病毒或感染有包含gp120病毒的细胞。本发明还提供了一种用于检测、结合、滴定（定量）、去除、纯化或分离（或将治疗或其他药物引导至）gp120的方法，该gp120包括病毒或感染有包含gp120病毒的细胞。本发明进一步提供了利用这些化合物的用途，以及用于将抗病毒药物或其他药物引导至含有gp120的病毒或含有gp120病毒感染细胞的方法。本发明还提供了用于制备这些新型化合物的工艺。
• [EN] 4-TOLYL-ETHYNYL-OCTAHYDRO-INDOLE-1-ESTER DERIVATIVES<br/>[FR] DÉRIVÉS DE 4-TOLYL-ÉTHYNYL-OCTAHYDRO-INDOLE-1-ESTER
  申请人：NOVARTIS AG

  公开号：WO2012101058A1

  公开（公告）日：2012-08-02

  The invention relates to compounds of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them.

  该发明涉及以下式（I）的化合物，其中取代基如规范中定义；以自由形式或盐形式存在；其制备方法，作为药物的用途以及包含它们的药物。